Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Kyverna Therapeutics
Mivocabtagene autoleucel is an autologous CD4- and CD8-positive T-cell therapy transduced with a lentiviral vector encoding an anti-CD19 chimeric antigen receptor with CD28 and CD3-zeta signaling domains. The engineered T cells recognize and lyse CD19-expressing B cells. It is studied in myasthenia gravis, progressive multiple sclerosis, rheumatoid arthritis, ANCA-associated vasculitis and lupus nephritis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06193889 | Phase 2/3 | Myasthenia Gravis | Recruiting | KYTX |
| NCT06590545 | Phase 1/2 | ANCA-IgG-positive ANCA Associated Vasculitis | Not yet recruiting | KYTX |
| NCT06475495 | Phase 1/2 | Rheumatoid Arthritis | Active not recruiting | KYTX |
| NCT06342960 | Phase 1/2 | Lupus Nephritis | Terminated | KYTX |
| NCT06451159 | Phase 1 | Progressive Multiple Sclerosis | Active not recruiting | KYTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
ANCA-IgG-positive ANCA Associated VasculitisGeneralized Myasthenia GravisMyasthenia GravisProgressive Multiple SclerosisRheumatoid ArthritisLupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV
Updated Oct 11, 2026. Something wrong or missing? Report it on the KYTX page.
See KYTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYTX catalysts and pipeline →